

2026 WDC China Summit: *Science into clinical practice*

Guangzhou, China


14–15 November 2026

In person

Outline Agenda

Day One — Saturday, 14 November 2026


Time	Session
08:30 – 09:00	Registration and welcome coffee
09:00 – 09:20	Opening remarks
09:20 – 10:30	Keynote and Plenary Conversation: Understanding the scientific basis for earlier diagnosis and intervention <i>How today’s research is reshaping expectations about when and how dementia can be identified.</i>
10:45 – 12:15	Keynote and Plenary Conversation: Delivering Treatments — lessons from the first wave of implementation <i>Insights from clinical sites and health systems delivering disease-modifying therapies.</i>
12:15 – 13:30	Lunch
13:30 – 15:00	Keynote and parallel session 1: Diagnostic criteria <i>How harmonised criteria enable scale, consistency, and equitable access across systems.</i> Keynote and parallel session 2: Data and AI <i>How and when will big data and AI reshape Alzheimer’s clinical trials by improving patient selection, reducing variability in cognitive assessment, and enabling more adaptive study designs.</i>
15:00	Coffee break
15:20 – 16:45	Keynote and parallel session 3: Biomarkers — scientific evidence, validation, and readiness for clinical use <i>Examining which biomarkers are ready for clinical practice and what evidence remains necessary.</i> Keynote and parallel session 4: Designing Health Systems for the Next Era of Dementia <i>As earlier diagnosis, prevention strategies, and new treatments become possible, health systems will need to evolve. This session will consider what long-term system architecture is required to support sustained monitoring, continuity of care, equitable</i>



	<i>access to interventions, and integration across primary care, specialist services, and community settings.</i>
17:00	End of Day One

Day Two — Sunday, 15 November 2026

Time	Session
08:45 – 09:15	Arrival coffee
09:15 – 10:30	<p>Keynote and parallel session 5: Life Course intervention, From Evidence to Implementation in dementia risk reduction <i>Research on risk reduction in at risk populations is now robust, yet implementation remains uneven. This session will examine how prevention can be embedded into health systems, workplace and community settings</i></p> <p>Keynote and Parallel Session 6: Diagnosing Before Symptoms — Redefining the Patient Journey <i>As biomarkers and diagnostic tools improve, identifying Alzheimer’s disease before noticeable cognitive symptoms will become increasingly common. This session will consider what it means to diagnose in the pre-symptomatic or very early symptomatic stage</i></p>
10:30 – 10:50	Coffee break
10:50 – 12:15	<p>Keynote and parallel session 5: Secondary prevention, interventions for an at risk population <i>This session will explore what secondary prevention looks like in practice: which interventions have evidence, how risk can be communicated and supported over time, and what it means to sustain engagement.</i></p> <p>Keynote and Parallel Session 7: Building Dementia Treatment Registries <i>How real-world data shapes clinical practice, safety, and long-term outcomes</i> <i>As disease-modifying therapies are introduced, treatment registries are becoming central to understanding how these therapies perform outside clinical trials. This session will examine different models for building and sustaining dementia registries</i></p>
12:15 – 13:30	Lunch
13:30 – 15:00	<p>Keynote and Plenary Conversation: Brain health <i>This session will examine how brain health connects to cardiovascular disease, mental health, metabolic conditions, and wider healthy ageing strategies. The discussion will explore whether brain health can serve as a unifying framework, what evidence is needed to support adoption, and how different sectors—from primary care to education and workplaces—can contribute.</i></p>
15:00 – 15:20	Coffee break
15:20 – 16:15	Keynote and Plenary Conversation: Advancing science into clinical practice — what collaboration is required next?



	<i>Reflections on strategic priorities and shared action across research, policy, and clinical delivery.</i>
16:15 – 16:30	Closing reflections
16:30	End of Summit